Immune dysfunction has been associated with children with autism. In clinical study, the participant’s overall aberrant behaviors decreased substantially soon after receiving their first dose of IVIG. IVIG has been proven to inhibit NF-kappaB activation induced by inflammatory cytokines such as TNF-alpha. Non-specific inflammatory markers; increased platelets and ESR (erythrocyte sedimentation rate), autoantibodies to myelin basic protein, thyroid antibodies, confirmed biopsies for colitis, low immunoglobulin levels, elevated anti-DNASE and anti-streptolysin O titers, all indicators of autoimmune disease, have been positively affected by IVIG. Decreases in hyperactivity, inappropriate speech, irritability, lethargy and stereotypy were proven. A NIH Consensus Statement asserted that the risks involved in the use of IVIG are minimal. After many years of experience, the safety of IVIG has been established. Thus, there is a reasonable rationale considering the risk/reward ratio to utilize IVIG therapy in children with autism.